If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Article
2019

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

Larkin, J., Brown, M. P., Arance, A. M., Hauschild, A., Queirolo, P., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., Garbe, C., Sileni, V. C., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G., Lorigan, P., Nyakas, M., Guminski, A., Liszkay, G. & 5 others, Rutkowski, P., Miller, W., Donica, M., Makrutzki, M. & Blank, C., Jan 2019, In : European Journal of Cancer. 107, p. 175-185 11 p.

Research output: Contribution to journalArticle

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

Larkin, J., Brown, M. P., Arance, A. M., Hauschild, A., Queirolo, P., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., Garbe, C., Sileni, V. C., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G., Lorigan, P., Nyakas, M., Guminski, A., Liszkay, G. & 5 others, Rutkowski, P., Miller, W., Donica, M., Makrutzki, M. & Blank, C., Jan 1 2019, In : European Journal of Cancer. 107, p. 175-185 11 p.

Research output: Contribution to journalArticle

Open Access

Combination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma: A Retrospective Analysis

Galli, G., Cavalieri, S., Di Guardo, L., Cimminiello, C., Nichetti, F., Corti, F., Garcia, M. A., Pappalardi, B., Fallai, C., De Braud, F., Platania, M. & Del Vecchio, M., Apr 1 2019, In : Oncology Research and Treatment. 42, 4, p. 182-188 7 p.

Research output: Contribution to journalArticle

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma: Nature Medicine

Ascierto, P. A., Ferrucci, P. F., Fisher, R., Del Vecchio, M., Atkinson, V., Schmidt, H., Schachter, J., Queirolo, P., Long, G. V., Di Giacomo, A. M., Svane, I. M., Lotem, M., Bar-Sela, G., Couture, F., Mookerjee, B., Ghori, R., Ibrahim, N., Moreno, B. H. & Ribas, A., 2019, In : Nat. Med.. 25, 6, p. 941-946 6 p.

Research output: Contribution to journalArticle

Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma

Indini, A., Di Guardo, L., Cimminiello, C., Prisciandaro, M., Randon, G., De Braud, F. & Del Vecchio, M., Jan 1 2019, (Accepted/In press) In : Tumori.

Research output: Contribution to journalArticle

Effectiveness of dabrafenib in the treatment of patients with braf v600-mutated metastatic melanoma in a named patient program: Melanoma Research

Martin-Algarra, S., Hinshelwood, R., Mesnage, S., Cebon, J., Ferrucci, P. F., Aglietta, M., Neyns, B., Chiarion-Sileni, V., Lindsay, C. R., Del Vecchio, M., Linardou, H., Merelli, B., Tonini, G., Atkinson, V., Freivogel, K., Stein, D., Dalland, L., Lau, M., Legenne, P., Queirolo, P. & 1 others, Millward, M., 2019, In : Melanoma Res.. 29, 5, p. 527-532 6 p.

Research output: Contribution to journalArticle

Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program

Martin-Algarra, S., Hinshelwood, R., Mesnage, S., Cebon, J., Ferrucci, P. F., Aglietta, M., Neyns, B., Chiarion-Sileni, V., Lindsay, C. R., Del Vecchio, M., Linardou, H., Merelli, B., Tonini, G., Atkinson, V., Freivogel, K., Stein, D., Dalland, L., Lau, M., Legenne, P., Queirolo, P. & 1 others, Millward, M., 2019, In : Melanoma Research. 29, 5, p. 527-532 6 p.

Research output: Contribution to journalArticle

Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program

Martin-Algarra, S., Hinshelwood, R., Mesnage, S., Cebon, J., Ferrucci, P. F., Aglietta, M., Neyns, B., Chiarion-Sileni, V., Lindsay, C. R., Del Vecchio, M., Linardou, H., Merelli, B., Tonini, G., Atkinson, V., Freivogel, K., Stein, D., Dalland, L., Lau, M., Legenne, P., Queirolo, P. & 1 others, Millward, M., Oct 1 2019, In : Melanoma Research. 29, 5, p. 527-532 6 p.

Research output: Contribution to journalArticle

Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program

Martin-Algarra, S., Hinshelwood, R., Mesnage, S., Cebon, J., Ferrucci, P. F., Aglietta, M., Neyns, B., Chiarion-Sileni, V., Lindsay, C. R., Del Vecchio, M., Linardou, H., Merelli, B., Tonini, G., Atkinson, V., Freivogel, K., Stein, D., Dalland, L., Lau, M., Legenne, P., Queirolo, P. & 1 others, Millward, M., 2019, In : Melanoma Research. 29, 5, p. 527-532 6 p.

Research output: Contribution to journalArticle

Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma

Indini, A., Di Guardo, L., Cimminiello, C., Prisciandaro, M., Randon, G., De Braud, F. & Del Vecchio, M., Feb 13 2019, In : Journal of Cancer Research and Clinical Oncology. 145, 2, p. 511-521 11 p.

Research output: Contribution to journalArticle

Open Access

Pembrolizumab in the treatment of advanced/metastatic melanoma: A single-center institution experience

Cimminiello, C., Indini, A., Di Guardo, L., Prisciandaro, M., Randon, G., Tolomio, E., De Braud, F. & Del Vecchio, M., Jun 1 2019, In : Melanoma Research. 29, 3, p. 289-294 6 p.

Research output: Contribution to journalArticle

The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors

Intergroup, I. M., Massi, D., Rulli, E., Cossa, M., Valeri, B., Rodolfo, M., Merelli, B., De Logu, F., Nassini, R., Del Vecchio, M., Di Guardo, L., De Penni, R., Guida, M., Sileni, V. C., Di Giacomo, A. M., Tucci, M., Occelli, M., Portelli, F., Vallacchi, V., Consoli, F. & 9 others, Quaglino, P., Queirolo, P., Baroni, G., Carnevale-Schianca, F., Cattaneo, L., Minisini, A., Palmieri, G., Rivoltini, L. & Mandalà, M., Nov 15 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, p. 1-13 13 p., 308.

Research output: Contribution to journalArticle

The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors

Massi, D., Rulli, E., Cossa, M., Valeri, B., Rodolfo, M., Merelli, B., De Logu, F., Nassini, R., Del Vecchio, M., Di Guardo, L., De Penni, R., Guida, M., Sileni, V. C., Di Giacomo, A. M., Tucci, M., Occelli, M., Portelli, F., Vallacchi, V., Consoli, F., Quaglino, P. & 10 others, Queirolo, P., Baroni, G., Carnevale-Schianca, F., Cattaneo, L., Minisini, A., Palmieri, G., Rivoltini, L., Mandalà, M., Simi, S. & Galli, F., 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1

Research output: Contribution to journalArticle

2018

Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting

De Santis, F., Del Vecchio, M., Castagnoli, L., De Braud, F., Di Cosimo, S., Franceschini, D., Fucà, G., Hiscott, J., Malmberg, K. J., McGranahan, N., Pietrantonio, F., Rivoltini, L., Sangaletti, S., Tagliabue, E., Tripodo, C., Vernieri, C., Zitvogel, L., Pupa, S. M. & Di Nicola, M., Dec 2018, In : Cytokine and Growth Factor Reviews. 44, p. 1-10 10 p.

Research output: Contribution to journalArticle

KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma

Ascierto, P. A., Ferrucci, P. F., Stephens, R., Del Vecchio, M., Atkinson, V., Schmidt, H., Schachter, J., Queirolo, P., Long, G. V., Di Giacomo, A. M., Svane, I., Lotem, M., Bar-Sela, G., Couture, F., Mookerjee, B. P., Ghori, R., Ibrahim, N., Homet Moreno, B. & Ribas, A., Oct 1 2018, In : Annals of oncology : official journal of the European Society for Medical Oncology. 29, p. viii442

Research output: Contribution to journalArticle

Open Access
2017

Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., Grob, J-J., Butler, M. O., Middleton, M. R., Maio, M., Atkinson, V., Queirolo, P., Gonzalez, R., Kudchadkar, R. R., Smylie, M., Meyer, N. & 14 others, Mortier, L., Atkins, M. B., Long, G. V., Bhatia, S., Lebbé, C., Rutkowski, P., Yokota, K., Yamazaki, N., Kim, T. M., De Pril, V., Sabater, J., Qureshi, A., Larkin, J. & Ascierto, P. A., 2017, In : New England Journal of Medicine. 377, 19, p. 1824-1835 12 p.

Research output: Contribution to journalArticle

Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., Grob, J-J., Butler, M. O., Middleton, M. R., Maio, M., Atkinson, V., Queirolo, P., Gonzalez, R., Kudchadkar, R. R., Smylie, M., Meyer, N. & 14 others, Mortier, L., Atkins, M. B., Long, G. V., Bhatia, S., Lebbé, C., Rutkowski, P., Yokota, K., Yamazaki, N., Kim, T. M., De Pril, V., Sabater, J., Qureshi, A., Larkin, J. & Ascierto, P. A., Nov 9 2017, In : New England Journal of Medicine. 377, 19, p. 1824-1835 12 p.

Research output: Contribution to journalArticle

Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., Grob, J-J., Butler, M. O., Middleton, M. R., Maio, M., Atkinson, V., Queirolo, P., Gonzalez, R., Kudchadkar, R. R., Smylie, M., Meyer, N. & 15 others, Mortier, L., Atkins, M. B., Long, G. V., Bhatia, S., Lebbé, C., Rutkowski, P., Yokota, K., Yamazaki, N., Kim, T. M., De Pril, V., Sabater, J., Qureshi, A., Larkin, J., Ascierto, P. A. & Guidoboni, M., 2017, In : New England Journal of Medicine. 377, 19, p. 1824-1835 12 p.

Research output: Contribution to journalArticle

Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., Grob, J. J., Butler, M. O., Middleton, M. R., Maio, M., Atkinson, V., Queirolo, P., Gonzalez, R., Kudchadkar, R. R., Smylie, M., Meyer, N. & 15 others, Mortier, L., Atkins, M. B., Long, G. V., Bhatia, S., Lebbé, C., Rutkowski, P., Yokota, K., Yamazaki, N., Kim, T. M., De Pril, V., Sabater, J., Qureshi, A., Larkin, J., Ascierto, P. A. & for the CheckMate 238 Collaborators, Nov 9 2017, In : New England Journal of Medicine. 377, 19, p. 1824-1835 12 p.

Research output: Contribution to journalArticle

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

Dummer, R., Schadendorf, D., Ascierto, P. A., Arance, A., Dutriaux, C., Di Giacomo, A. M., Rutkowski, P., Del Vecchio, M., Gutzmer, R., Mandala, M., Thomas, L., Demidov, L., Garbe, C., Hogg, D., Liszkay, G., Queirolo, P., Wasserman, E., Ford, J., Weill, M., Sirulnik, L. A. & 4 others, Jehl, V., Bozón, V., Long, G. V. & Flaherty, K., Apr 2017, In : The Lancet Oncology. 18, 4, p. 435-445 11 p.

Research output: Contribution to journalArticle

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

Dummer, R., Schadendorf, D., Ascierto, P. A., Arance, A., Dutriaux, C., Di Giacomo, A. M., Rutkowski, P., Del Vecchio, M., Gutzmer, R., Mandala, M., Thomas, L., Demidov, L., Garbe, C., Hogg, D., Liszkay, G., Queirolo, P., Wasserman, E., Ford, J., Weill, M., Sirulnik, L. A. & 4 others, Jehl, V., Bozón, V., Long, G. V. & Flaherty, K., 2017, In : The Lancet Oncology. 18, 4, p. 435-445 11 p.

Research output: Contribution to journalArticle

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

Davies, M. A., Saiag, P., Robert, C., Grob, J. J., Flaherty, K. T., Arance, A., Chiarion-Sileni, V., Thomas, L., Lesimple, T., Mortier, L., Moschos, S. J., Hogg, D., Márquez-Rodas, I., Del Vecchio, M., Lebbé, C., Meyer, N., Zhang, Y., Huang, Y., Mookerjee, B. & Long, G. V., Jul 1 2017, In : The Lancet Oncology. 18, 7, p. 863-873 11 p.

Research output: Contribution to journalArticle

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

Davies, M. A., Saiag, P., Robert, C., Grob, J-J., Flaherty, K. T., Arance, A., Chiarion-Sileni, V., Thomas, L., Lesimple, T., Mortier, L., Moschos, S. J., Hogg, D., Márquez-Rodas, I., Del Vecchio, M., Lebbé, C., Meyer, N., Zhang, Y., Huang, Y., Mookerjee, B. & Long, G. V., 2017, In : The Lancet Oncology. 18, 7, p. 863-873 11 p.

Research output: Contribution to journalArticle

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

Ascierto, P. A., Del Vecchio, M., Robert, C., Mackiewicz, A., Chiarion-Sileni, V., Arance, A., Lebbé, C., Bastholt, L., Hamid, O., Rutkowski, P., McNeil, C., Garbe, C., Loquai, C., Dreno, B., Thomas, L., Grob, J-J., Liszkay, G., Nyakas, M., Gutzmer, R., Pikiel, J. & 10 others, Grange, F., Hoeller, C., Ferraresi, V., Smylie, M., Schadendorf, D., Mortier, L., Svane, I. M., Hennicken, D., Qureshi, A. & Maio, M., May 2017, In : The Lancet Oncology. 18, 5, p. 611-622 12 p.

Research output: Contribution to journalArticle

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

Ascierto, P. A., Del Vecchio, M., Robert, C., Mackiewicz, A., Chiarion-Sileni, V., Arance, A., Lebbé, C., Bastholt, L., Hamid, O., Rutkowski, P., McNeil, C., Garbe, C., Loquai, C., Dreno, B., Thomas, L., Grob, J-J., Liszkay, G., Nyakas, M., Gutzmer, R., Pikiel, J. & 10 others, Grange, F., Hoeller, C., Ferraresi, V., Smylie, M., Schadendorf, D., Mortier, L., Svane, I. M., Hennicken, D., Qureshi, A. & Maio, M., 2017, In : The Lancet Oncology. 18, 5, p. 611-622 12 p.

Research output: Contribution to journalArticle

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

Ascierto, P. A., Del Vecchio, M., Robert, C., Mackiewicz, A., Chiarion-Sileni, V., Arance, A., Lebbé, C., Bastholt, L., Hamid, O., Rutkowski, P., McNeil, C., Garbe, C., Loquai, C., Dreno, B., Thomas, L., Grob, J-J., Liszkay, G., Nyakas, M., Gutzmer, R., Pikiel, J. & 11 others, Grange, F., Hoeller, C., Ferraresi, V., Smylie, M., Schadendorf, D., Mortier, L., Svane, I. M., Hennicken, D., Qureshi, A., Maio, M. & Guidoboni, M., 2017, In : The Lancet Oncology. 18, 5, p. 611-622 12 p.

Research output: Contribution to journalArticle

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma

Blank, C. U., Larkin, J., Arance, A. M., Hauschild, A., Queirolo, P., Del Vecchio, M., Ascierto, P. A., Krajsova, I., Schachter, J., Neyns, B., Garbe, C., Chiarion Sileni, V., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G. A. P., Miller, W. H., Robson, S., Makrutzki, M., Antic, V. & 1 others, Brown, M. P., Jul 2017, In : European Journal of Cancer. 79, p. 176-184 9 p.

Research output: Contribution to journalArticle

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis

Blank, C. U., Larkin, J., Arance, A. M., Hauschild, A., Queirolo, P., Del Vecchio, M., Ascierto, P. A., Krajsova, I., Schachter, J., Neyns, B., Garbe, C., Chiarion Sileni, V., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G. A. P., Miller, W. H., Robson, S., Makrutzki, M., Antic, V. & 1 others, Brown, M. P., Jul 2017, In : European Journal of Cancer. 79, p. 176-184 9 p.

Research output: Contribution to journalArticle

2016

Aggiornamento AACR dei dati di sopravvivenza a 5 anni, efficacia e sicurezza a lungo termine in pazienti con melanoma metastatico avanzato che ricevono mono-immunoterapia con nivolumab

Translated title of the contribution: AACR update on 5-year survival rates, efficacy and long-term safety in previously treated advanced/metastatic melanoma patients receiving mono-immunotherapy with nivolumabDel Vecchio, M., Aug 2016, In : Recenti Progressi in Medicina. 107, 8, p. 414-7 4 p.

Research output: Contribution to journalArticle

Baseline neutrophils and derived neutrophilto-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab

Ferrucci, P. F., Ascierto, P. A., Pigozzo, J., Del Vecchio, M., Maio, M., Antonini Cappellini, G. C., Guidoboni, M., Queirolo, P., Savoia, P., Mandalà, M., Simeone, E., Valpione, S., Altomonte, M., Spagnolo, F., Cocorocchio, E., Gandini, S., Giannarelli, D. & Martinoli, C., Apr 1 2016, In : Annals of Oncology. 27, 4, p. 732-738 7 p., mdw016.

Research output: Contribution to journalArticle

Baseline neutrophils and derived neutrophilto-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab

Ferrucci, P. F., Ascierto, P. A., Pigozzo, J., Del Vecchio, M., Maio, M., Antonini Cappellini, G. C., Guidoboni, M., Queirolo, P., Savoia, P., Mandalà, M., Simeone, E., Valpione, S., Altomonte, M., Spagnolo, F., Cocorocchio, E., Gandini, S., Giannarelli, D. & Martinoli, C., Apr 1 2016, In : Annals of Oncology. 27, 4, p. 732-738 7 p., mdw016.

Research output: Contribution to journalArticle

Baseline neutrophils and derived neutrophilto-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab

Ferrucci, P. F., Ascierto, P. A., Pigozzo, J., Del Vecchio, M., Maio, M., Antonini Cappellini, G. C., Guidoboni, M., Queirolo, P., Savoia, P., Mandalà, M., Simeone, E., Valpione, S., Altomonte, M., Spagnolo, F., Cocorocchio, E., Gandini, S., Giannarelli, D. & Martinoli, C., Apr 1 2016, In : Annals of Oncology. 27, 4, p. 732-738 7 p., mdw016.

Research output: Contribution to journalArticle

Baseline neutrophils and derived neutrophilto-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab

Ferrucci, P. F., Ascierto, P. A., Pigozzo, J., Del Vecchio, M., Maio, M., Antonini Cappellini, G. C., Guidoboni, M., Queirolo, P., Savoia, P., Mandalà, M., Simeone, E., Valpione, S., Altomonte, M., Spagnolo, F., Cocorocchio, E., Gandini, S., Giannarelli, D. & Martinoli, C., Apr 1 2016, In : Annals of Oncology. 27, 4, p. 732-738 7 p., mdw016.

Research output: Contribution to journalArticle

Baseline neutrophils and derived neutrophilto-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab

Ferrucci, P. F., Ascierto, P. A., Pigozzo, J., Del Vecchio, M., Maio, M., Antonini Cappellini, G. C., Guidoboni, M., Queirolo, P., Savoia, P., Mandalà, M., Simeone, E., Valpione, S., Altomonte, M., Spagnolo, F., Cocorocchio, E., Gandini, S., Giannarelli, D. & Martinoli, C., Apr 1 2016, In : Annals of Oncology. 27, 4, p. 732-738 7 p., mdw016.

Research output: Contribution to journalArticle

CARAMEL study: Clinical prognostic biomarkers for ipilimumab-related outcome in metastatic melanoma patients

Orgiano, L., Bruder, F., Madeddu, C., Marconcini, R., Gambale, E., Galizia, E., Stucci, S., Spagnolo, F., Di Guardo, L., Loi, C., Pani, F., Massa, D., Massa, E., Astara, G., Del Vecchio, M., Silvestris, F., de tursi, M., Falcone, A., Queirolo, P. & Scartozzi, M., Oct 1 2016, In : Annals of Oncology. 27, p. vi386

Research output: Contribution to journalArticle

Open Access

Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: The INT Milan experience

Cavalieri, S., Di Guardo, L., Cimminiello, C., Bono, A., Tolomio, E., Colombetti, A., Valeri, B., Di Tolla, G., De Braud, F. & Del Vecchio, M., Sep 1 2016, In : Tumori. 102, 5, p. 501-507 7 p.

Research output: Contribution to journalArticle

Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib

Queirolo, P., Spagnolo, F., Picasso, V., Spano, L., Tanda, E., Fontana, V., Giorello, L., Merlo, D. F., Simeone, E., Grimaldi, A. M., Curvietto, M., Del Vecchio, M., Bruzzi, P. & Ascierto, P. A., Jul 13 2016, In : Oncotarget.

Research output: Contribution to journalArticle

Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib.

Queirolo, P., Spagnolo, F., Picasso, V., Spano, L., Tanda, E., Fontana, V., Giorello, L., Merlo, D. F., Simeone, E., Grimaldi, A. M., Curvietto, M., Del Vecchio, M., Bruzzi, P. & Ascierto, P. A., Jul 1 2016, In : Oncotarget.

Research output: Contribution to journalArticle

2015

A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification

Dugo, M., Nicolini, G., Tragni, G., Bersani, I., Tomassetti, A., Colonna, V., Vecchio, M. D., Braud, F. D., Canevari, S., Anichini, A. & Sensi, M., 2015, In : Oncotarget. 6, 7, p. 5118-5133 16 p.

Research output: Contribution to journalArticle

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma

Hersh, E. M., Del Vecchio, M., Brown, M. P., Kefford, R., Loquai, C., Testori, A., Bhatia, S., Gutzmer, R., Conry, R., Haydon, A., Robert, C., Ernst, S., Homsi, J., Grob, J. J., Kendra, K., Agarwala, S. S., Li, M., Clawson, A., Brachmann, C., Karnoub, M. & 3 others, Elias, I., Renschler, M. F. & Hauschild, A., Nov 1 2015, In : Annals of Oncology. 26, 11, p. 2267-2274 8 p., mdv324.

Research output: Contribution to journalArticle